Robert Lefkowitz on his 50 years at Duke. Congratulations. Dr. coupled receptors Industry News Duke University Celebrates Nobel Prize Winner Robert Lefkowitz’s 50 Years

Recent years have seen cryo-EM dominate new GPCR structure determinations, offering insight into GPCR-effector Future perspectives In recent years, remarkable strides have been taken in unraveling the intricacies

disease therapy Primary cilia in skeletal development and disease Industry News Addex Reports 2023 Half Year

Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics To Release Half-Year

GPCR-targeted Medicines OMass Therapeutics was shortlisted for ‘Life Sciences and Health Tech Company of the Year

This year's symposium will feature a trainee day with a career panel.

In ACKR3, the presence of a tyrosine at position 6.40 plays a role in its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han, Tachado et al. 2012, Yen,

collaboration of data across academia, industry, and regulatory bodies will likely increase in the coming years

Orion Biotechnology will be participating in a panel discussion at the LSX World Congress Novel living yeast-based

likely to be mediated by changes in the cell motility machinery with receptor-specific switches not yet

Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Addex Reports Full Year Corporate Update Sosei Heptares Announces the Publication of its Inaugural ESG Report, for the Financial Year with curriculum and deep reinforcement learning Structure Therapeutics Reports Fourth Quarter and Full Year

Exscientia Business and Financial Update for the Full Year 2022.

Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year

GPCR Therapeutics on Beyond Biotech Podcast Crinetics Pharmaceuticals Reports Fourth Quarter And Full Year

funding into small biotech companies developing novel technology platforms to target GPCRs in recent years Within the last two years, three investments stand out: · Tectonic Therapeutics: received $80 There is a great deal of scientific and business interest in solving this problem, and the last two years

Hello Readers👋, Happy New Year! We're excited to be back and share our weekly newsletter! Industry News Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust

However, at that time the structural conformation of the transmembrane (TM) region was not yet known. Fortunately, the scientific community has become increasingly interested in studying these proteins and this year

ADGRL3 (LPHN3) and Two Pseudogenes "We report the finding of two copy number variants (CNVs) in a 12-year-old

receptors "Neural network (NN)-based protein modeling methods have improved significantly in recent years

These details are often challenging to quantitatively assess yet are essential for our understanding

greatly impact the treatment of CVD with unprecedented benefits which will be revealed in the next years

AHH who shared characteristics with the 2 cases we previously reported as follows: (a) elderly (74-87 years

2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet

2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet

variants that result from alternative splicing have been identified and the majority of these isoforms are yet

research, case numbers and overall mortality remain high and have trended upwards over the last few years

Yet, despite this upregulation, associated physiological effects are not observed in AD patients.

Aims: The pathophysiological mechanism(s) underlying non-alcoholic fatty liver disease (NAFLD) have yet